Home » Authors » Brady Huggett

Articles by Brady Huggett

Rigel Raises $31.5M To Move First Product Into Clinic In 2002

Jan. 18, 2002

By Brady Huggett

Maxim Begins Ceplene Phase III With Liver Metastases Patients

Jan. 18, 2002

By Brady Huggett

Rigel Raises $31.5M To Move First Product Into Clinic In 2002

Jan. 18, 2002

By Brady Huggett

Immunex’s Enbrel Continues Growth, Receives 4th Approval

Jan. 17, 2002

By Brady Huggett

Immunex’s Enbrel Continues Growth, Receives 4th Approval

Jan. 17, 2002

By Brady Huggett

Aderis Files For $100M IPO With Parkinson’s Product In Phase III

Jan. 15, 2002

By Brady Huggett

Aderis Files For $100M IPO With Parkinson’s Product In Phase III

Jan. 15, 2002

By Brady Huggett

Antigenics Raises $60M From Shelf For Oncophage Trials

Jan. 14, 2002

By Brady Huggett

Antigenics Raises $60M From Shelf For Oncophage Trials

Jan. 14, 2002

By Brady Huggett

Hyseq Buying Amgen Compound To Move First Product Into Clinic

Jan. 10, 2002

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...